Clinical Trial Update: (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors [Phase 3]

View source ↗

Summary

A Phase 3 randomized trial compares CGT9486 plus sunitinib versus sunitinib alone in advanced or metastatic gastrointestinal stromal tumors; the study is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• CGT9486 (PLX9486)
• Sutent (sunitinib)

Snippet

Sponsor: Cogent Biosciences, Inc. | Conditions: Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING